Quel est le prix pour Psyence Biomedical Ltd. (PBM)

Le prix pour Psyence Biomedical Ltd. (PBM) est $3.20

Quelle est la capitalisation boursière pour Psyence Biomedical Ltd. (PBM)

La capitalisation boursière pour Psyence Biomedical Ltd. (PBM) est $60.86K

Psyence Biomedical Ltd. (PBM) Historique des Prix

Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.

Année	Performance
2026 (TTM)	8.63%
2025	-91.56%
2024	0.00%

Année

Performance

2026 (TTM)

8.63%

2025

-91.56%

2024

0.00%

Entreprise	Prix de l'action	Variation 1a%	Pays
Vertex Pharmaceuticals Incorporated VRTX.US	$523.97	32.34%	US
Argenx SE ARGX.US	$867.22	34.12%	NL
Lonza Group AG LONN.SW	$744.96	8.94%	CH
Samsung Biologics Co.,Ltd. 207940.KS	$1.08K	-6.68%	KR
UCB S.A. UCB.BR	$259.89	16.65%	BE

Entreprise

Prix de l'action

Variation 1a%

Pays